Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 61 to 70 of 2245 total matches.

Alcaftadine (Lastacaft) for Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2011  (Issue 1359)
Alcaftadine Lastacaft (Allergan) 1 drop 1x/d B $105.60 (0.25% soln*) (3 mL) Azelastine generic 1 drop bid ...
Alcaftadine (Lastacaft – Allergan), an ophthalmic H1-antihistamine, has been approved by the FDA for prevention of itching associated with allergic conjunctivitis in patients > 2 years old.
Med Lett Drugs Ther. 2011 Mar 7;53(1359):19-20 | Show Introduction Hide Introduction

Extended-Release Exenatide (Bydureon) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2012  (Issue 1386)
glucagon-like peptide-1 (GLP-1) receptor agonist, for treatment of type 2 diabetes. Table 1. Pharmacology ...
The FDA has approved a once-weekly extendedrelease formulation of exenatide (Bydureon – Amylin), an injectable glucagon-like peptide-1 (GLP-1) receptor agonist, for treatment of type 2 diabetes.
Med Lett Drugs Ther. 2012 Mar 19;54(1386):21-3 | Show Introduction Hide Introduction

Drugs for Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021  (Issue 1622)
and whether they are are intermittent or persistent (see Table 1).1 H1-ANTIHISTAMINES — Oral second ...
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19;63(1622):57-64 | Show Introduction Hide Introduction

Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Feb 01, 2016  (Issue 1487)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1487) February 1, 2016 Published ...
The FDA has approved rolapitant (Varubi – Tesaro), an oral substance P/neurokinin 1 (NK1) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
Med Lett Drugs Ther. 2016 Feb 1;58(1487):17-8 | Show Introduction Hide Introduction

Lifitegrast (Xiidra) for Dry Eye Disease

   
The Medical Letter on Drugs and Therapeutics • Aug 29, 2016  (Issue 1502)
of lifitegrast (Xiidra – Shire), a lymphocyte functionassociated antigen-1 (LFA-1) antagonist, for treatment ...
The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist to be approved for any indication in the US.
Med Lett Drugs Ther. 2016 Aug 29;58(1502):110-1 | Show Introduction Hide Introduction

Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2011  (Issue 1360)
subsequently require treatment with more than one drug.1 Many combination products have been marketed ...
Metformin (Glucophage, and others) is generally preferred as the first-line agent for treatment of type 2 diabetes, but most patients subsequently require treatment with more than one drug. Many combination products have been marketed; the latest of these combines saxagliptin with extended-release (ER) metformin as Kombiglyze XR.
Med Lett Drugs Ther. 2011 Mar 21;53(1360):21-2 | Show Introduction Hide Introduction

Sofosbuvir (Sovaldi) for Chronic Hepatitis C

   
The Medical Letter on Drugs and Therapeutics • Jan 20, 2014  (Issue 1434)
treatment with sofosbuvir are shown in table 2.3-5 Table 1. Pharmacology Class Nucleotide polymerase ...
The FDA has approved the nucleotide polymerase inhibitor sofosbuvir (Sovaldi – Gilead) for use in combination with other antiviral drugs for treatment of chronic hepatitis C virus (HCV) infection.
Med Lett Drugs Ther. 2014 Jan 20;56(1434):5-6 | Show Introduction Hide Introduction

An EUA for Bamlanivimab and Etesevimab for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021  (Issue 1621)
(see Table 1).1 Bamlanivimab received an EUA for use as monotherapy in such patients in November ...
The FDA has issued an Emergency Use Authorization (EUA) for Lilly's investigational monoclonal antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) to be administered together for treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease and/or hospitalization (see Table 1). Bamlanivimab received an EUA for use as monotherapy in such patients in November 2020. Regeneron's investigational monoclonal antibodies casirivimab (REGN10933) and imdevimab (REGN10987) are also authorized for use...
Med Lett Drugs Ther. 2021 Apr 5;63(1621):49-50 | Show Introduction Hide Introduction

Angeliq for Treatment of Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Feb 12, 2007  (Issue 1254)
properties. Drospirenone is also available in the combination oral contraceptives Ya z and Yasmin. 1 ...
A combination tablet containing estradiol and drospirenone (Angeliq - Berlex) recently became available for treatment of moderate to severe menopausal symptoms in women with an intact uterus. Since the last Medical Letter issue reviewing such devices,1 more continuous glucose monitoring (CGM) systems have become available. Five devices available now, and two expected to be marketed soon, are listed in the table on page 14. The FDA has approved continuous glucose devices only for the observation of glucose trends.
Med Lett Drugs Ther. 2007 Feb 12;49(1254):15-6 | Show Introduction Hide Introduction

A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018  (Issue 1539)
hepatitis B component as Engerix-B and is licensed for use only in adults. 1 Table 1. Hepatitis B Vaccines ...
The FDA has approved a two-dose hepatitis B virus (HBV) vaccine (Heplisav-B – Dynavax) for use in adults ≥18 years old. The three other HBV vaccines marketed in the US are usually administered in 3 doses. Engerix-B and Recombivax HB are licensed for use in persons of all ages. A combination hepatitis A/B vaccine (Twinrix) contains the same hepatitis B component as Engerix-B and is licensed for use only in adults.
Med Lett Drugs Ther. 2018 Jan 29;60(1539):17-8 | Show Introduction Hide Introduction